Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR3 | Q99500 | 10/20 | 0.51 |
| ▸ | FBP1 | P09467 | 2/20 | 0.47 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.43 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19899756 | 0.89 | KCNH2 (0.52) | FBP1MAPTPSMB8KCNH2MEN1 | |
| SCHEMBL19899642 | 0.83 | NPC1 (0.36) | S1PR3FBP1MAPTRAB9AMEN1 | |
| SCHEMBL19899502 | 0.83 | NPC1 (0.44) | S1PR3PIK3CGMAPTRAB9ABACE1 | |
| SCHEMBL19899596 | 0.83 | ESR1 (0.44) | RAB9AGAA | |
| SCHEMBL19899622 | 0.83 | NPC1 (0.38) | S1PR3MAPTRAB9AS1PR1BACE1 | |
| SCHEMBL19899752 | 0.82 | HDAC7 (0.44) | S1PR3FBP1MAPTRAB9AKCNH2 | |
| SCHEMBL19899660 | 0.82 | NPC1 (0.38) | S1PR3MAPTRAB9AS1PR1BACE1 | |
| SCHEMBL19899788 | 0.80 | CSNK2A2 (0.34) | S1PR3MAPTRAB9AGAA | |
| SCHEMBL19914359 | 0.80 | NPBWR1 (0.41) | MAPTRAB9ABACE1MEN1GAA | |
| SCHEMBL19900225 | 0.80 | ALDH1A1 (0.40) | S1PR3MAPTRAB9AS1PR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | claimed |
| EP-3500567-A1 | ANTIBIOTIC COMPOUNDS | Discuva Ltd. (GB) | 2019-06-26 | — | — | EP | claimed |
| WO-2018037223-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2018-03-01 | — | — | WO | claimed |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2019-06-27 | — | — | US | disclosed |
| EP-3500567-A1 | ANTIBIOTIC COMPOUNDS | Discuva Ltd. (GB) | 2019-06-26 | — | — | EP | disclosed |
| WO-2018037223-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2018-03-01 | — | — | WO | disclosed |
| WO-2018037223-A1 | ANTIBIOTIC COMPOUNDS | DISCUVA LTD. (GB) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194179-A1 | ANTIBIOTIC COMPOUNDS | B3GNT2, RPN2, RPN1 | S1PR3 4068/4885FBP1 724/4885PIK3CG 1306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.